REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN the Treatment of DEPRESSION
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00220610|
Recruitment Status : Unknown
Verified September 2005 by St. Lucas Andreas Ziekenhuis Hospital.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
Subjects received rTMS daily on 10 consecutive weekdays (five sessions per week), during 20 minutes per session.During the rTMS session, the coil was centered flat over the right parietal cortex.
We follow the patient during 12 weeks after the 2 weeks of tms (follow-up period) to measure the depression with different rating scales.
We hypothesized that rTMS has a positive effect in the treatment of depression
|Condition or disease||Intervention/treatment||Phase|
|Depression||Device: Transcranial magnetic stimulation||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Right Parietal Inhibition With rTMS in the Treatment of Depression|
|Study Start Date :||May 2004|
|Study Completion Date :||December 2006|
- To determine the depression (and so the effect of the treatment)we use the 10-item Montgomery Asberg Depression Rating Scale (MADRS)and we measure before tms (T=0), at week 1 (T=1), at week 2 (T=2), at week 4 (T=3), at week 8 (T=4), at week 14 (T=5)
- Besides the MADRS we use the BDI (Beck depression Inventory, the Hamillton deppression and anxiety scale)
- -Changes in anxiety
- -.Autonomic changes
- -.changes in the emotioneal attention, in the emotional memory en in de emotional recognition.
- -.Biochemical changes
- -.Changes in the EEG
- >> measured before tms and after (at T=0 and T=2)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00220610
|Contact: Judith van der Riet, Drs.||email@example.com|
|st. Lucas Andreas Ziekenhuis/ Hospital||Recruiting|
|Amsterdam, Netherlands, 1061 AE|
|Contact: Judith van der Riet, Drs 0031-20-5108562 firstname.lastname@example.org|
|Contact: G.F Koerselman, Prof.dr. 0031-20-5108562 email@example.com|
|Study Director:||G.F Koerselman, prof. dr.||st Lucas Andreas Ziekenhuis|